一例移植后复发MPN经PD-1阻断治疗中JAK2V617F+AML与供者T细胞的共进化
本文报告一例MPN异基因HSCT后复发患者接受nivolumab(PD-1阻断)治疗,在治疗前、中、后6个时间点采集外周血单个核细胞,整合单细胞RNA测序、TCR测序、CITE-seq、scATAC-seq及质谱流式分析。基线时AML原始细胞高表达趋化因子、T细胞表达干扰素应答基因,输注nivolumab后该炎症特征消失;临床应答表现为多克隆CD4+ T细胞短暂扩增及具有巨核细胞特征且PD-L1高表达的AML亚群收缩,复发时祖细胞样AML亚群比例逐渐增加,提示AML原始细胞与供者T细胞共进化。
要点
- 移植后复发MPN经PD-1阻断可出现临床应答,伴多克隆CD4+ T细胞短暂扩增。
- 应答相关AML亚群具巨核细胞特征且PD-L1高表达,治疗后该亚群收缩。
- 复发时祖细胞样AML亚群比例逐渐增加,提示AML与供者T细胞共进化。
核心结论
- PD-1阻断后临床应答表现为多克隆CD4+ T细胞短暂扩增和具巨核细胞特征且PD-L1高表达的AML亚群收缩,复发时祖细胞样AML亚群比例逐渐增加,提示AML原始细胞与供者来源T细胞共进化。
研究设计与样本
- 一例MPN异基因HSCT后复发接受PD-1阻断(nivolumab)治疗的指示病例。
- 在PD-1阻断前、中、后6个时间点采集外周血单个核细胞。
- 整合单细胞RNA测序、T细胞受体测序、CITE-seq、scATAC-seq及质谱流式进行高维分析。
主要发现
- nivolumab输注前AML原始细胞高表达趋化因子,T细胞表达干扰素应答基因。
- nivolumab输注后基线炎症特征消失。
- 临床应答伴随多克隆CD4+ T细胞群体短暂扩增。
- 临床应答伴随具巨核细胞特征且PD-L1表达升高的AML亚群收缩。
- 复发时具祖细胞样特征的AML亚群比例逐渐增加。
临床怎么用
- 单细胞技术可提供PD-1阻断应答细胞机制的互补信息,支持对复发髓系疾病GVL反应开展纵向高维单细胞研究。
局限性
- 本文为单例指示病例报告,结论需在更多患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse of myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with poor outcomes, as therapeutic approaches to reinstate effective graft-versus-leukemia (GVL) responses remain suboptimal. Immune escape through overexpression of PD-L1 in JAK2V617F-mutated MPN provides a rationale for therapeutic PD-1 blockade, and indeed, clinical activity of nivolumab in relapsed MPN post-HSCT has been observed. Elucidation of the features of response following PD-1 blockade in such patients could inform novel therapeutic concepts that enhance GVL. Here, we report an integrated high-dimensional analysis using single-cell RNA sequencing, T-cell receptor sequencing, cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), and assay for transposase-accessible chromatin using sequencing (scATAC-seq), together with mass cytometry, in peripheral blood mononuclear cells collected at 6 timepoints before, during, and after transient response to PD-1 blockade from an index case of relapsed MPN following HSCT. Before nivolumab infusion, acute myeloid leukemia (AML) blasts demonstrated high expression of chemokines, and T cells were characterized by expression of interferon-response genes. This baseline inflammatory signature disappeared after nivolumab infusion. Clinical response was characterized by transient expansion of a polyclonal CD4+ T-cell population and contraction of an AML subpopulation that exhibited megakaryocytic features and elevated PD-L1 expression. At relapse, the proportion of the AML subpopulation with progenitor-like features progressively increased, suggesting coevolution of AML blasts and donor-derived T cells. We thus demonstrate how single-cell technologies can provide complementary insight into cellular mechanisms underlying response to PD-1 blockade, motivating future longitudinal high-dimensional single-cell studies of GVL responses in relapsed myeloid disease.
引用
- Penter L, Gohil SH, Huang T, et al. Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv. 2021. PMID: 34432868. doi:10.1182/bloodadvances.2021004335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。